

25 May 2026

Long Term Aqual™ Licensing and Supply Agreement with The Skin Health Institute

Highlights:

- **Argent BioPharma enters long-term licensing and supply agreement with The Skin Health Institute Ltd**
- **Agreement provides exclusive worldwide use of Aqual™ for dermatology focused cosmetic applications**
- **Aqual™ is based on the developed SNEEDS technology platform designed to improve bioavailability and topical delivery of large particles**
- **Expands application of Argent BioPharma's drug delivery technologies into dermatology and skin health markets**

Argent BioPharma Ltd (ASX: RGT) (Argent or the Company) is pleased to announce the execution of a long-term licensing and supply agreement with The Skin Health Institute Ltd (SHI) (trading as MGC Derma), an Ireland-based dermatology and skin health company, relating to the MGC Derma platform, Aqual™, and associated clinically tested dermatology products.

The agreement follows SHI's previous acquisition of the MGC Derma¹ brand and establishes a new long term framework covering licensing, manufacturing, supply, royalties, and commercial collaboration in relation to dermatology focused formulations and related intellectual property, continuing for five years unless terminated by either party.


Under the agreement, SHI receives an exclusive worldwide licence to utilise Aqual™ and associated formulations for the manufacturing, marketing, and distribution of dermatology focused cosmetic products. The agreement also establishes a long-term supply arrangement under which SHI will source Aqual™ and related dermatological products from Argent BioPharma on arm's length, commercial terms.

The arrangement includes a fixed monthly royalty payment of €3,000 together with an additional revenue linked 5% royalty associated with the commercialisation of products incorporating Aqual™ and the MGC Derma platform.

MGC Derma is a clinically positioned dermocosmetic platform focused on inflammation control, skin barrier repair, and the management of sensitive and problematic skin. The platform is designed to support individuals experiencing reactive, compromised, or treatment stressed skin through targeted daily skincare protocols.

The formulations have previously undergone clinical testing conducted by Argent BioPharma and are supported by a science driven approach to skin barrier function and dermatological health.

¹ Refer to ASX announcement dated 13 November 2018



The Aqual™ platform is based on the jointly developed SNEEDS delivery technology platform, originally developed in collaboration with Graft Bio, designed to improve the bioavailability and topical delivery of larger particles through stable water-soluble formulation technology. The delivery platform forms part of Argent BioPharma's broader drug delivery and development portfolio and has also been utilised in pharmaceutical programmes including CimetrA®. Through this agreement, the Company is expanding the application of its delivery technologies into the dermatology and skin health sector via dermatologically tested skincare products.

Production, formulation development, and future expansion of additional products under the MGC Derma platform are expected to be conducted through Argent BioPharma's Slovenian operational partners at NutraMind, leveraging the Company's formulation capabilities, proprietary delivery system technologies, and integrated product development infrastructure

Argent BioPharma believes the agreement strategically expands the application of its anti-inflammatory, immune modulation, and drug delivery system (DDS) technologies beyond pharmaceutical indications into the dermatology and skin health sector, supporting the development of diversified healthcare revenue streams alongside the Company's broader neuro immune focused pipeline

MGC Derma is supported by an experienced advisory and commercial network spanning dermatology, medicine, premium beauty, and strategic growth, including former L'Oréal dermatologist expert Dr Michele Verschoore, former British Medical Association President Sir Pali Hungin, and senior commercial executives associated with brands including YSL and Burberry.

The Company further notes that the agreement includes collaboration provisions relating to potential commercial opportunities within the United States dermatology and cosmetic markets.

Roby Zomer, Chairman, commented:

"This agreement reflects Argent BioPharma's strategy of expanding the application of its proprietary delivery and formulation technologies beyond pharmaceuticals into clinically positioned skin health and dermatology markets. MGC Derma and Aqual™ provide a platform that combines clinically tested formulations, long-term supply economics, and differentiated delivery technologies within a growing global dermocosmetic sector"


—Ends—

Authorised for release by the board of directors, for further information please contact:

Argent BioPharma
Roby Zomer
Chairman
+61 8 6555 2950
info@argentbiopharma.com

Argent BioPharma
Rowan Harland
Company Secretary
+61 8 6555 2950
info@argentbiopharma.com





About Argent BioPharma

Argent BioPharma Ltd. (ASX: RGT) is a revenue-generating, clinical-stage biopharmaceutical company focused on the development and commercialisation of nano-engineered therapeutics targeting neurological and immune-mediated disorders. Its lead assets, CannEpi[®] and CimetrA[®], are being advanced for drug-resistant epilepsy and inflammatory conditions, respectively. The Company leverages proprietary nano-delivery technologies designed to optimise bioavailability and tissue penetration, including across the blood–brain barrier and pulmonary interfaces. With vertically integrated EU-GMP manufacturing, a unified Neuro-Immune Modulatory platform, and ongoing clinical development programs, Argent BioPharma is advancing a focused pipeline targeting central nervous system and systemic inflammatory conditions with significant unmet medical need.

About The Skin Health Institute Ltd (trading as MGC Derma)

MGC Derma is a clinically positioned dermocosmetic company focused on inflammation control, skin barrier repair, and the management of sensitive and problematic skin. The company is developing a science-led skincare platform designed to support individuals experiencing reactive, compromised, or treatment-stressed skin through targeted daily skincare protocols. Combining clinically tested formulations with a strong focus on barrier function and skin health, MGC Derma is building a differentiated position within the growing global dermocosmetic market across pharmacy, clinic, and professional skincare channels. The company is supported by an experienced advisory network spanning dermatology, medicine, premium beauty, and strategic growth, including former L'Oréal dermatologist expert Dr Michele Verschoore, former British Medical Association President Sir Pali Hungin, and senior commercial figures from brands including YSL and Burberry"

